Quintin Robinson, MD
Infectious Disease · Atlanta, GANPI 1760684658
Payments from drug & device makers
Across 849 payments — averaging $331.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$176K
- Gilead$88K
- Merck$12K
- Theratechnologies Inc.$2K
- GSK$902
- EMD Serono, Inc.$499
- plus $2K from 19 others
Across 3 payments — averaging $25.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$77
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 389 | $175,536 |
| Gilead | 219 | $88,408 |
| Merck | 65 | $11,924 |
| Theratechnologies Inc. | 21 | $1,973 |
| GSK | 11 | $902 |
| EMD Serono, Inc. | 40 | $499 |
| Johnson & Johnson | 40 | $454 |
| AbbVie | 12 | $260 |
| Novo Nordisk | 12 | $214 |
| Janssen Products, LP | 2 | $200 |
| Lilly USA, LLC | 9 | $185 |
| Astellas Pharma US Inc | 5 | $164 |
| Octapharma USA, Inc. | 1 | $92 |
| Verity Pharmaceuticals Inc. | 4 | $63 |
| Antares Pharma, Inc. | 3 | $55 |
| Napo Pharmaceuticals Inc | 3 | $49 |
| Exact Sciences | 3 | $43 |
| Abbott | 2 | $41 |
| Pfizer | 2 | $28 |
| Halozyme Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $17 |
| CSL Behring | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
How this compares
$281,187 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Atlanta
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Zandraetta Tims-CookAtlanta$878K
- Scott FridkinAtlanta$774K
- Colleen KelleyAtlanta$738K
- Leandro MenaAtlanta$733K
- Srilatha EdupugantiAtlanta$726K
- Larry AndersonAtlanta$694K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.